Read by QxMD icon Read

Yale goal

Lori Berard, Noreen Antonishyn, Kathryn Arcudi, Sarah Blunden, Alice Cheng, Ronald Goldenberg, Stewart Harris, Shelley Jones, Upender Mehan, James Morrell, Robert Roscoe, Rick Siemens, Michael Vallis, Jean-François Yale
It is currently estimated that 11 million Canadians are living with diabetes or prediabetes. Although hyperglycemia is associated with serious complications, it is well established that improved glycemic control reduces the risk of microvascular complications and can also reduce cardiovascular (CV) complications over the long term. The UKPDS and ADVANCE landmark trials have resulted in diabetes guidelines recommending an A1C target of ≤ 7.0% for most patients or a target of ≤ 6.5% to further reduce the risk of nephropathy and retinopathy in those with type 2 diabetes (T2D), if it can be achieved safely...
February 23, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
Xiqian Huo, Erica S Spatz, Qinglan Ding, Paul Horak, Xin Zheng, Claire Masters, Haibo Zhang, Melinda L Irwin, Xiaofang Yan, Wenchi Guan, Jing Li, Xi Li, John A Spertus, Frederick A Masoudi, Harlan M Krumholz, Lixin Jiang
INTRODUCTION: Mobile health interventions have the potential to promote risk factor management and lifestyle modification, and are a particularly attractive approach for scaling across healthcare systems with limited resources. We are conducting two randomised trials to evaluate the efficacy of text message-based health messages in improving secondary coronary heart disease (CHD) prevention among patients with or without diabetes. METHODS AND ANALYSIS: The Cardiovascular Health And Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study are multicentre, single-blind, randomised controlled trials of text messaging versus standard treatment with 6 months of follow-up conducted in 37 hospitals throughout 17 provinces in China...
December 21, 2017: BMJ Open
Kerin Adelson, Donald K K Lee, Salimah Velji, Junchao Ma, Susan K Lipka, Joan Rimar, Peter Longley, Teresita Vega, Javier Perez-Irizarry, Edieal Pinker, Rogerio Lilenbaum
PURPOSE: End-of-life care for patients with advanced cancer is aggressive and costly. Oncologists inconsistently estimate life expectancy and address goals of care. Currently available prognostication tools are based on subjective clinical assessment. An objective prognostic tool could help oncologists and patients decide on a realistic plan for end-of-life care. We developed a predictive model (Imminent Mortality Predictor in Advanced Cancer [IMPAC]) for short-term mortality in hospitalized patients with advanced cancer...
December 5, 2017: Journal of Oncology Practice
Sean D Hood, Annabel Broyd, Hayley Robinson, Jessica Lee, Abdul-Rahman Hudaib, Dana A Hince
BACKGROUND: Serotonergic antidepressants are first-line medication therapies for obsessive-compulsive disorder, however it is not known if synaptic serotonin availability is important for selective serotonin reuptake inhibitor efficacy. The present study tested the hypothesis that temporary reduction in central serotonin transmission, through acute tryptophan depletion, would result in an increase in anxiety in selective serotonin reuptake inhibitor-remitted obsessive-compulsive disorder patients...
December 2017: Journal of Psychopharmacology
Jerry W Sayre, Hale Z Toklu, Fan Ye, Joseph Mazza, Steven Yale
Case reports and case series or case study research are descriptive studies that are prepared for illustrating novel, unusual, or atypical features identified in patients in medical practice, and they potentially generate new research questions. They are empirical inquiries or investigations of a patient or a group of patients in a natural, real-world clinical setting. Case study research is a method that focuses on the contextual analysis of a number of events or conditions and their relationships. There is disagreement among physicians on the value of case studies in the medical literature, particularly for educators focused on teaching evidence-based medicine (EBM) for student learners in graduate medical education...
August 7, 2017: Curēus
Philip Coish, Bryan W Brooks, Evan P Gallagher, Margaret Mills, Terrance J Kavanagh, Nancy Simcox, Grace A Lasker, Dianne Botta, Stephanie C Schmuck, Adelina Voutchkova-Kostal, Jakub Kostal, Melissa L Mullins, Suzanne M Nesmith, Karolina E Mellor, Jone Corrales, Lauren A Kristofco, Gavin N Saari, W Baylor Steele, Longzhu Q Shen, Fjodor Melnikov, Julie B Zimmerman, Paul T Anastas
Herein we provide an overview of a research collaborative aimed at fostering interdisciplinary collaboration between chemists and toxicologists with the aim of rationally designing safer commercial chemicals. The collaborative, Molecular Design Research Network (MoDRN), was created in 2013 with funding from the EPA-NSF Networks for Sustainable Molecular Design and Synthesis program. It is a collaboration led by four universities, Baylor University, University of Washington, The George Washington University, and Yale University...
August 30, 2017: Toxicological Sciences: An Official Journal of the Society of Toxicology
Stefan Avey, Subhasis Mohanty, Jean Wilson, Heidi Zapata, Samit R Joshi, Barbara Siconolfi, Sui Tsang, Albert C Shaw, Steven H Kleinstein
Motivation: Systems immunology leverages recent technological advancements that enable broad profiling of the immune system to better understand the response to infection and vaccination, as well as the dysregulation that occurs in disease. An increasingly common approach to gain insights from these large-scale profiling experiments involves the application of statistical learning methods to predict disease states or the immune response to perturbations. However, the goal of many systems studies is not to maximize accuracy, but rather to gain biological insights...
July 15, 2017: Bioinformatics
Roseli G Shavitt, Guaraci Requena, Pino Alonso, Gwyneth Zai, Daniel L C Costa, Carlos Alberto de Bragança Pereira, Maria Conceição do Rosário, Ivanil Morais, Leonardo Fontenelle, Carolina Cappi, James Kennedy, Jose M Menchon, Euripedes Miguel, Peggy M A Richter
Current research to explore genetic susceptibility factors in obsessive-compulsive disorder (OCD) has resulted in the tentative identification of a small number of genes. However, findings have not been readily replicated. It is now broadly accepted that a major limitation to this work is the heterogeneous nature of this disorder, and that an approach incorporating OCD symptom dimensions in a quantitative manner may be more successful in identifying both common as well as dimension-specific vulnerability genetic factors...
October 3, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
Christie M Ballantyne, Sukrut Shah, Aditi Sapre, Tanya B Ashraf, Sandra C Tobias, Tayfun Sahin, Ping Ye, Yugang Dong, Wayne Huey-Heng Sheu, Duk-Hyun Kang, Paulo Roberto Ferreira Rossi, Yulia Moiseeva, Ignacio Rodriguez Briones, Amy O Johnson-Levonas, Yale B Mitchel
This phase 3, multiregional, randomized, double-blind, placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were not at their low-density lipoprotein (LDL-C) goal (as per the National Cholesterol Education Program Adult Treatment Panel III guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C). Patients on a stable dose of statin ± other lipid-modifying therapies and with LDL-C ≥70 to <115, ≥100 to <145, ≥130, or ≥160 mg/dl for very high, high, moderate, or low CHD risk or at LDL-C goal (per CHD risk category) with HDL-C ≤40 mg/dl were randomized in a ratio of 1:1 to anacetrapib 100 mg (n = 290) or placebo (n = 293) for 24 weeks, followed by a 12-week off-drug phase...
August 15, 2017: American Journal of Cardiology
Graydon S Meneilly, Lori D Berard, Alice Y Y Cheng, Peter J Lin, Lori MacCallum, Ross T Tsuyuki, Jean-François Yale, Nahal Nasseri, Jean-François Richard, Lianne Goldin, Anatoly Langer, Mary K Tan, Lawrence A Leiter
OBJECTIVE: The Goal Oriented controL of Diabetes in the Elderly populatioN (GOLDEN) Program assessed the management of older persons with type 2 diabetes in Canadian primary care. METHODS: Data were extracted from the records of 833 consecutively identified persons 65 years of age or older who had type 2 diabetes and were taking 1 antihyperglycemic agent or more; they were managed by 64 physicians from 36 Ontario clinics. RESULTS: More than half (53%) had glycated hemoglobin (A1C) levels of 7...
June 2, 2017: Canadian Journal of Diabetes
Ron Kline, Kerin Adelson, Jeffrey J Kirshner, Larissa M Strawbridge, Marsha Devita, Naralys Sinanis, Patrick H Conway, Ethan Basch
Cancer care delivery in the United States is often fragmented and inefficient, imposing substantial burdens on patients. Costs of cancer care are rising more rapidly than other specialties, with substantial regional differences in quality and cost. The Centers for Medicare &amp; Medicaid Services (CMS) Innovation Center (CMMIS) recently launched the Oncology Care Model (OCM), which uses payment incentives and practice redesign requirements toward the goal of improving quality while controlling costs. As of March 2017, 190 practices were participating, with approximately 3,200 oncologists providing care for approximately 150,000 unique beneficiaries per year (approximately 20% of the Medicare Fee-for-Service population receiving chemotherapy for cancer)...
2017: American Society of Clinical Oncology Educational Book
Terra G Arnason, Matthew W Bowen, Kerry D Mansell
AIM: To determine the short-term biochemical effects and clinical tolerability of intermittent fasting (IF) in adults with type 2 diabetes mellitus (T2DM). METHODS: We describe a three-phase observational study (baseline 2 wk, intervention 2 wk, follow-up 2 wk) designed to determine the clinical, biochemical, and tolerability of IF in community-dwelling volunteer adults with T2DM. Biochemical, anthropometric, and physical activity measurements (using the Yale Physical Activity Survey) were taken at the end of each phase...
April 15, 2017: World Journal of Diabetes
Xiaowei Zhao, Feiping Nie, Sen Wang, Jun Guo, Pengfei Xu, Xiaojiang Chen
In recent years, unsupervised two-dimensional (2D) dimensionality reduction methods for unlabeled large-scale data have made progress. However, performance of these degrades when the learning of similarity matrix is at the beginning of the dimensionality reduction process. A similarity matrix is used to reveal the underlying geometry structure of data in unsupervised dimensionality reduction methods. Because of noise data, it is difficult to learn the optimal similarity matrix. In this letter, we propose a new dimensionality reduction model for 2D image matrices: unsupervised 2D dimensionality reduction with adaptive structure learning (DRASL)...
May 2017: Neural Computation
Bulat A Ziganshin, Mitra Sadigh, Liliya M Yausheva, Anna P Ziganshina, Arseniy A Pichugin, Alexey S Sozinov, Nail Kh Amirov, Asghar Rastegar, Ayrat U Ziganshin, Majid Sadigh
BACKGROUND: The partnership between Yale University (USA) and Kazan State Medical University (KSMU, Russia) was established in 1996 and transitioned to Western Connecticut Health Network (WCHN)/University of Vermont Robert Larner, M.D. College of Medicine (USA) in 2012 with the goal of modernizing medical education at KSMU primarily through introduction of the American medical education structure, role modeling, and educational capacity building. It was centered on the formation of a select group of Russian junior faculty members familiar with American medical education who would then initiate a gradual change in medical education at KSMU...
January 25, 2017: BMC Medical Education
Bo Xu, Nicolas Bettinger, Changdong Guan, Björn Redfors, Yuejin Yang, Bao Li, Yaling Han, Xi Su, Zuyi Yuan, Philippe Généreux
OBJECTIVES: We sought to study whether the level of completeness of revascularization as measured by the SYNTAX revascularization index (SRI) independently predicts adverse ischemic events after percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES). BACKGROUND: The SRI quantifies the proportion of revascularized myocardium. It has been shown to independently predict adverse ischemic events after PCI with first-generation DES. METHODS: Among 1,900 patients enrolled in a registry to evaluate safety and effectiveness of everolimus drug-eluting stent (SEEDS) for coronary revascularization, the SRI was calculated and available for 1,851 patients...
March 2017: Catheterization and Cardiovascular Interventions
Jakob D Jensen, Robert N Yale, Melinda Krakow, Kevin K John, Andy J King
Narratives are common in health campaigns and interventions, with many depicting individuals battling a particular illness or disease. Past research has focused primarily on the form and effects of survivor stories, but considerably less attention has been devoted to stories in which 1 or more of the central characters passes away. The goal of the current study was to compare the relative persuasive impact of survivor and death narratives in influencing skin prevention behaviors and to test narrative mediators that might explicate underlying mechanisms of effect...
January 2017: Journal of Health Communication
Ronald M Goldenberg, Lori D Berard, Alice Y Y Cheng, Jeremy D Gilbert, Subodh Verma, Vincent C Woo, Jean-François Yale
PURPOSE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of antihyperglycemic agents available on the market. Regulator warnings and concerns regarding the risk of developing diabetic ketoacidosis (DKA), however, have dampened enthusiasm for the class despite the combined glycemic, blood pressure, and occasional weight benefits of SGLT2 inhibitors. With the goal of improving patient safety, a cross-Canada expert panel and writing group were convened to review the evidence to-date on reported SGLT2 inhibitor-related DKA incidents and to offer recommendations for preventing and recognizing patients with SGLT2 inhibitor-associated DKA...
December 2016: Clinical Therapeutics
Christie M Ballantyne, Sukrut Shah, Uma Kher, John A Hunter, Geraldine G Gill, Michael D Cressman, Tanya B Ashraf, Amy O Johnson-Levonas, Yale B Mitchel
To assess the effects of anacetrapib added to statin ± other lipid-modifying therapies in patients with hypercholesterolemia and not at their low-density lipoprotein cholesterol (LDL-C) goal (as per National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C). Patients on a stable dose of moderate/high-intensity statin ± other lipid-modifying therapies with LDL-C ≥70, ≥100, ≥130, or ≥160 mg/dl for very high, high, moderate, and low coronary heart disease risk, respectively, or at LDL-C goal with HDL-C ≤40 mg/dl, were randomized 1:1:1, stratified by background therapy use, to anacetrapib 100 mg (n = 153), anacetrapib 25 mg (n = 152), or placebo (n = 154) for 24 weeks, followed by a 12-week off-drug reversal phase...
February 1, 2017: American Journal of Cardiology
Justyna Mojsa-Kaja, Krystyna Golonka, Magda Gawłowska
OBJECTIVES: Obsessive-compulsive disorder (OCD) is an anxiety-spectrum disorder that affects 1-2% of the adult population. People with OCD are more likely to report impaired social and occupational functioning. Although effective treatments of the OCD exist, many sufferers from this disorder are continuously misdiagnosed. Therefore, improving the assessment of the OCD remains an important area of scientific research. The main goal of the study is the initial verification of psychometric properties in the Polish version of the Obsessive-Compulsive Inventory-Revised (OCI-R) in a college student sample...
November 18, 2016: International Journal of Occupational Medicine and Environmental Health
Kerin B Adelson, Salimah Velji, Kavita Patel, Basit Chaudhry, Catherine Lyons, Rogerio Lilenbaum
Most cancer centers are ill-equipped to pursue value-based payment (VBP) because of limited information on their population's cost of care. Herein, we outline the stepwise approach used by Smilow Cancer Hospital at Yale-New Haven in our pursuit of better value care. First, we addressed institutional barriers. A move toward value required demonstration to Yale-New Haven Health System leadership that OCM would improve patient care, fund new infrastructure, and provide the opportunity to gain experience with VBP without a major threat to the financial stability of the health system...
October 2016: Journal of Oncology Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"